How to Improve the Safe and Effective Use of Doxorubicin in Children with Cancer

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 2015 Jul 1

PMID 26123706

Citations 4

Authors

John N van den Anker

Affiliations

Soon will be listed here.

Citing Articles

A database of pediatric drug effects to evaluate ontogenic mechanisms from child growth and development.

Giangreco N, Tatonetti N Med. 2022; 3(8):579-595.e7.

PMID: 35752163 PMC: 9378670. DOI: 10.1016/j.medj.2022.06.001.

Effects of genetic polymorphisms on the sulfation of doxorubicin by human SULT1C4 allozymes.

Gohal S, Rasool M, Bairam A, Alatwi E, Alherz F, Abunnaja M J Biochem. 2021; 170(3):419-426.

PMID: 33950190 PMC: 8510289. DOI: 10.1093/jb/mvab055.

Chemotherapy induced damage to spermatogonial stem cells in prepubertal mouse in vitro impairs long-term spermatogenesis.

Lopes F, Tholeti P, Adiga S, Anderson R, Mitchell R, Spears N Toxicol Rep. 2021; 8:114-123.

PMID: 33425685 PMC: 7782321. DOI: 10.1016/j.toxrep.2020.12.023.

Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.

Krischke M, Hempel G, Voller S, Andre N, DIncalci M, Bisogno G Cancer Chemother Pharmacol. 2016; 78(6):1175-1184.

PMID: 27770238 PMC: 5114325. DOI: 10.1007/s00280-016-3174-8.

References

Visscher H, Ross C, Rassekh S, Barhdadi A, Dube M, Al-Saloos H . Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2011; 30(13):1422-8. DOI: 10.1200/JCO.2010.34.3467. View

Lipshultz S, Adams M . Cardiotoxicity after childhood cancer: beginning with the end in mind. J Clin Oncol. 2010; 28(8):1276-81. DOI: 10.1200/JCO.2009.26.5751. View

Tukenova M, Guibout C, Oberlin O, Doyon F, Mousannif A, Haddy N . Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010; 28(8):1308-15. DOI: 10.1200/JCO.2008.20.2267. View

Lee J, Aminkeng F, Bhavsar A, Shaw K, Carleton B, Hayden M . The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clin Genet. 2014; 86(1):21-8. PMC: 4233969. DOI: 10.1111/cge.12392. View

Voller S, Boos J, Krischke M, Wurthwein G, Kontny N, Boddy A . Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer. Clin Pharmacokinet. 2015; 54(11):1139-49. DOI: 10.1007/s40262-015-0272-4. View

Gregers J, Green H, Christensen I, Dalhoff K, Schroeder H, Carlsen N . Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2015; 15(4):372-9. PMC: 4762905. DOI: 10.1038/tpj.2014.81. View

Palle J, Frost B, Peterson C, Gustafsson G, Hellebostad M, Kanerva J . Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. Anticancer Drugs. 2006; 17(4):385-92. DOI: 10.1097/01.cad.0000198911.98442.16. View

Ellison L, De P, Mery L, Grundy P . Canadian cancer statistics at a glance: cancer in children. CMAJ. 2009; 180(4):422-4. PMC: 2638027. DOI: 10.1503/cmaj.081155. View

van der Pal H, van Dalen E, Hauptmann M, Kok W, Caron H, van den Bos C . Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med. 2010; 170(14):1247-55. DOI: 10.1001/archinternmed.2010.233. View

10.

Visscher H, Ross C, Rassekh S, Sandor G, Caron H, van Dalen E . Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer. 2013; 60(8):1375-81. DOI: 10.1002/pbc.24505. View